{
    "nct_id": "NCT04620330",
    "official_title": "A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)",
    "inclusion_criteria": "* Male or female subjects ≥ 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS or BRAF mutation\n* The subject must have received appropriate prior therapy\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* History of treatment with a direct and specific inhibitor of MEK, KRAS or BRAF except for treatment of BRAF V-600E mutant NSCLC\n* Exposure to strong CYP2C9 and CYP3A4 inhibitors or inducers within 7 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions.\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy\n* Active skin disorder that has required systemic therapy within the past 1 year\n* History of rhabdomyolysis\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Subjects with the inability to swallow oral medications",
    "miscellaneous_criteria": ""
}